Oxcarbazepine
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Oxcarbazepine: Restless legs syndrome
One-Sentence Summary
Oxcarbazepine is an antiseizure medication originally used for partial (focal) epilepsy. The TxGNN model predicts it may be effective for restless legs syndrome with a very high score, but there are currently no registered clinical trials and the 16 retrieved publications are mostly general epilepsy reviews and guidelines with no restless-legs-syndrome-specific data on oxcarbazepine. The strongest signal in this prediction set is not for visual epilepsy but for restless legs syndrome, which has three case reports (see the “Other Predicted Indications” note below).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Restless legs syndrome |
| TxGNN Prediction Score | 0.9989 |
| Evidence Level | L4 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, oxcarbazepine acts mainly through its active metabolite (MHD) by blocking voltage-gated sodium channels, and its efficacy in focal seizures is established. Visual (photosensitive or occipital) epilepsy is a focal or reflex seizure phenotype, so a mechanistic link through the existing focal-epilepsy indication is plausible.
However, the retrieved literature consists of general antiseizure medication reviews and guidelines. The high TxGNN score probably reflects overlap with the approved epilepsy indication, and may reflect similarities the model learned between related diseases, rather than independent evidence for restless legs syndrome.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29898971 | 2018 | Guideline | Neurology | AAN/AES update on new antiepileptic drugs for new-onset focal or generalized epilepsy |
| 35380580 | 2022 | Review | JAMA | Review of antiseizure medications for adults with epilepsy |
| 33334546 | 2020 | Review | Seizure | Current role of carbamazepine and oxcarbazepine in epilepsy management |
| 39899099 | 2025 | Review | Continuum | Update on antiseizure medications: pharmacokinetics, indications and use |
| 11772334 | 2002 | Review | Expert Opin Pharmacother | Oxcarbazepine efficacy in partial seizures, trigeminal neuralgia; early data in neuropathic pain and bipolar disorder |
| 1379159 | 1992 | Review | Drugs | Pharmacology and therapeutic potential of oxcarbazepine in epilepsy, trigeminal neuralgia and affective disorders |
| 17560495 | 2007 | Review | Pediatr Neurol | Visual adverse effects of antiepileptic drugs (relevant to safety, not efficacy) |
| 26844734 | 2016 | Review | Continuum | Overview of antiepileptic drugs and their modes of use |
None of these publications addresses oxcarbazepine specifically in visual epilepsy.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02284294 | APO-OXCARBAZEPINE | Not listed | Not listed |
| 02244673 | TRILEPTAL ORAL SUSPENSION | Not listed | Not listed |
| 02242069 | TRILEPTAL 600 MG | Not listed | Not listed |
| 02242068 | TRILEPTAL 300 MG | Not listed | Not listed |
| 02284308 | APO-OXCARBAZEPINE | Not listed | Not listed |
One additional authorization (DIN 02284316, APO-OXCARBAZEPINE) is also valid. All six are single-ingredient products, and none is cancelled.
Safety Considerations
- Conditions flagged as contraindication-related in the knowledge graph (not taken from label text): anxiety disorder, neurotic disorder, dysthymic disorder, impaired renal function, inappropriate ADH syndrome, nephrogenic syndrome of inappropriate antidiuresis.
- Drug Interactions: 100 interactions were found, and the 20 reviewed are all of Moderate level. They include corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone), vitamin D forms (cholecalciferol, calcifediol, calcitriol), antidiabetics (pioglitazone, chlorpropamide, saxagliptin, linagliptin), omeprazole and dexlansoprazole, clarithromycin, morphine, aprepitant, dronabinol and eliglustat.
- Sodium channel blockers can aggravate some generalized epilepsies (for example, a reported oxcarbazepine case in juvenile myoclonic epilepsy, PMID 23774821). Correct seizure classification is therefore important before any off-label use.
Please also refer to the package insert for full warnings and contraindications.
Other Predicted Indications
| Rank | Predicted Indication | Evidence Level | Key Evidence | Recommendation |
|---|---|---|---|---|
| 2 | Restless legs syndrome | L4 | Three case reports of successful treatment (19483488), one case of paroxetine-induced RLS (16675374), and a narrative review; no controlled trials | Research Question |
| 3 | Eating seizures | L5 | Retrieved papers unrelated | Hold |
| 4 | Orgasm-induced seizures | L5 | No trials, no literature | Hold |
| 5 | Thinking seizures | L4 | Mostly mouse electroshock studies and general reviews | Hold |
| 6 | Startle epilepsy | L5 | No trials, no literature | Hold |
| 7 | Audiogenic seizures | L4 | Preclinical DBA/2 mouse studies only | Hold |
| 8 | Micturition-induced seizures | L5 | General epilepsy reviews only | Hold |
| 9 | Status epilepticus | L4 | Case reports with mixed direction (one use in refractory cases, one aggravation); no parenteral formulation | Hold |
| 10 | Reading seizures | L4 | Indirect evidence from other reflex epilepsies; some case reports describe oxcarbazepine helping hot-water and cold-induced reflex epilepsy | Hold |
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for restless legs syndrome rests on the model score and a plausible link through the existing focal-epilepsy indication. No clinical trials exist, and the retrieved literature contains no restless-legs-syndrome-specific oxcarbazepine data. Safety data from the package insert are also not yet available, so safety screening cannot proceed.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (currently missing and blocking safety screening)
- Detailed mechanism of action data
- Targeted literature search for oxcarbazepine in visual, photosensitive and occipital epilepsy
- Consideration of a formal research question for restless legs syndrome, where case-level evidence is most specific
- Dosage form and approved indication details for the six Canadian licences
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.